{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036938","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.254310+00:00","generated_at":"2026-05-31T09:36:01.998841+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin Therapeutics reports Q2 2024 net loss of $12.4M; NAVIGATE interim readout on track for Dec 2024","bullets":["NAVIGATE Phase 2b/3 trial of belapectin on track for interim top-line analysis in December 2024.","Cash and equivalents of $25.6M at June 30, 2024; $10M line of credit from chairman available.","Net loss for Q2 2024 was $12.4M ($0.20 per share) vs $9.2M ($0.15 per share) in Q2 2023.","R&D expenses rose to $9.8M from $7.4M, driven by NAVIGATE trial costs.","Cash runway expected to fund operations through approximately May 15, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036938","json":"https://secwatch.observer/filing/0001140361-24-036938.json","markdown":"https://secwatch.observer/filing/0001140361-24-036938.md","text":"https://secwatch.observer/filing/0001140361-24-036938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124036938/0001140361-24-036938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124036938/ef20033852_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:36:01.998841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}